Skip to content

Patients with Eczema, Psoriasis and Xerosis

PCCA - Patients with Eczema, Psoriasis and Xerosis - Product Insight

PCCA XemaTop is a new compounding base created for formulations targeting patients with psoriasis, eczema (atopic dermatitis) and xerosis (dry skin). It uses the power and synergy of natural boswellic acid, avenanthramides from oats, phospatidylglycerol and elegant film formers to deliver and improve the action of common active pharmaceutical ingredients used in formulations for these patients.

XemaTop replenishes the lipids within the skin, nourishes the skin’s structural integrity and improves the appearance of red and irritated skin. XemaTop also quickly nourishes and replenishes the lamellar bilayers of the skin and helps restore health into the skin’s barrier to reduce the appearance of redness and irritation and to prevent water loss. Preparing medication with an ideal base like XemaTop combined with certain actives, such as those listed below, may create an affordable and perfect customised compound for your patient.

Common Active Pharmaceutical Ingredients that work well in combination with Clarifying Base include: Corticosteroids, Vitamin D and derivatives, Vitamin E and derivatives, Cyanocobalamin and Zinc pyrithione.PCCA - Patients with Eczema, Psoriasis and Xerosis - Product Insight

“The appearance of my two-year-old son’s arm was greatly improved in just seven days when I applied PCCA’s XemaTop.” Kristi Hughes; Houston, Texas, United States of America.

Patient Benefits:

  • Replenishes the lipids within the skin
  • Nourishes the skin’s structural integrity
  • Helps restore the skin’s barrier and prevent water loss
  • May be used with or without active ingredients

Dermatology and compounding are a natural fit, and creating customised skin care as unique as your patients is easy with the right tools and information. As we see statistics like the following ever increasing: Eczema is rapidly rising in Australia with as many as one in four children developing the disease before the age of two1 and Psoriasis is a common skin disorder, which affects 2.6% of Australians and 125 million people worldwide2, it is clear the need for compounded solutions are essential.

Would you like more information about PCCA Clarifying Base and XemaTop? Contact PCCA for more information: 02 9316 1500 or visit

1. Eczema Association of Australia
2. Psoriasis Australia, Psoriasis Understood

Share this article:

Articles you might be interested in

Scroll To Top